Identification of a New Panel of Serum Autoantibodies Associated with the Presence of In situ Carcinoma of the Breast in Younger Women
暂无分享,去创建一个
P. Rouanet | C. Bascoul-Mollevi | J. Solassol | A. Mangé | P. Lamy | T. Maudelonde | P. Rochaix | A. Kramar | C. Desmetz
[1] S. Hanash,et al. Occurrence of autoantibodies to annexin I, 14-3-3 theta and LAMR1 in prediagnostic lung cancer sera. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] J. Solassol,et al. Proteomic analysis of RCL2 paraffin-embedded tissues , 2008, Journal of cellular and molecular medicine.
[3] J. Koblinski,et al. Prolyl isomerase cyclophilin A regulation of Janus-activated kinase 2 and the progression of human breast cancer. , 2008, Cancer research.
[4] P. Rouanet,et al. Proteomics-based identification of HSP60 as a tumor-associated antigen in early stage breast cancer and ductal carcinoma in situ. , 2008, Journal of proteome research.
[5] Jian-ying Zhang,et al. Using proteomic approach to identify tumor-associated antigens as markers in hepatocellular carcinoma. , 2008, Journal of proteome research.
[6] L. Chouchane,et al. Identification of tumor antigens that elicit a humoral immune response in breast cancer patients' sera by serological proteome analysis (SERPA). , 2008, Clinica chimica acta; international journal of clinical chemistry.
[7] Hailing Lu,et al. Humoral immunity directed against tumor-associated antigens as potential biomarkers for the early diagnosis of cancer. , 2008, Journal of proteome research.
[8] B-W. Park,et al. Preoperative CA 15-3 and CEA serum levels as predictor for breast cancer outcomes. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.
[9] David E. Misek,et al. Identification of 14-3-3θ as an antigen that induces a humoral response in lung cancer , 2007 .
[10] A Murray,et al. Autoantibodies in lung cancer: possibilities for early detection and subsequent cure , 2007, Thorax.
[11] M. Alessio,et al. Autoantibody signature in human ductal pancreatic adenocarcinoma. , 2007, Journal of proteome research.
[12] L. Esserman,et al. A role for biomarkers in the screening and diagnosis of breast cancer in younger women , 2007, Expert review of molecular diagnostics.
[13] D. Knutson,et al. Screening for breast cancer: current recommendations and future directions. , 2007, American family physician.
[14] J. Robertson,et al. Autoantibodies in breast cancer: their use as an aid to early diagnosis. , 2007, Annals of oncology : official journal of the European Society for Medical Oncology.
[15] Sankey V. Williams,et al. Screening Mammography in Women 40 to 49 Years of Age: A Systematic Review for the American College of Physicians , 2007, Annals of Internal Medicine.
[16] Yuzhang Wu,et al. Proteomics‐based identification of HSP60 as a tumor‐associated antigen in colorectal cancer , 2007, Proteomics. Clinical applications.
[17] A. Shimizu,et al. Proteomics-Based Approach Identifying Autoantibody against Peroxiredoxin VI as a Novel Serum Marker in Esophageal Squamous Cell Carcinoma , 2006, Clinical Cancer Research.
[18] E. Tan,et al. Tumor-associated Antigen Arrays for the Serological Diagnosis of Cancer* , 2006, Molecular & Cellular Proteomics.
[19] A. Shimizu,et al. Detection of eight antibodies in cancer patients' sera against proteins derived from the adenocarcinoma A549 cell line using proteomics-based analysis. , 2006, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
[20] J. Blay,et al. Autoantibodies to endostatin in patients with breast cancer: correlation to endostatin levels and clinical outcome , 2006, British Journal of Cancer.
[21] M. Duffy,et al. Serum tumor markers in breast cancer: are they of clinical value? , 2006, Clinical chemistry.
[22] J. Robertson,et al. Malignancy-induced autoimmunity to MUC1: initial antibody characterization. , 2008, The journal of peptide research : official journal of the American Peptide Society.
[23] P. Ferrari,et al. Intensive post-operative follow-up of breast cancer patients with tumour markers: CEA, TPA or CA15.3 vs MCA and MCA-CA15.3 vs CEA-TPA-CA15.3 panel in the early detection of distant metastases , 2006, BMC Cancer.
[24] Xiao-Fan Wang,et al. Stable RNA interference-mediated suppression of cyclophilin A diminishes non-small-cell lung tumor growth in vivo. , 2005, Cancer research.
[25] S. Rhee,et al. Peroxiredoxins: a historical overview and speculative preview of novel mechanisms and emerging concepts in cell signaling. , 2005, Free radical biology & medicine.
[26] H. Chae,et al. Peroxiredoxin‐I is an autoimmunogenic tumor antigen in non‐small cell lung cancer , 2005, FEBS letters.
[27] R. Zhong,et al. Proteomics-based identification of DEAD-box protein 48 as a novel autoantigen, a prospective serum marker for pancreatic cancer. , 2005, Biochemical and biophysical research communications.
[28] M. Caron,et al. An efficient proteomics-based approach for the screening of autoantibodies. , 2005, Journal of immunological methods.
[29] Xiaoju Wang,et al. Autoantibodies to Annexin XI-A and Other Autoantigens in the Diagnosis of Breast Cancer , 2004, Cancer Research.
[30] D. McNeel,et al. Pre-existent immunity to the HER-2/neu oncogenic protein in patients with HER-2/neu overexpressing breast and ovarian cancer , 2000, Breast Cancer Research and Treatment.
[31] Kohzoh Imai,et al. Circulating anti‐MUC1 IgG antibodies as a favorable prognostic factor for pancreatic cancer , 2003, International journal of cancer.
[32] P. Marin,et al. Synaptic multiprotein complexes associated with 5‐HT2C receptors: a proteomic approach , 2002, The EMBO journal.
[33] Laura Beretta,et al. A Distinct Repertoire of Autoantibodies in Hepatocellular Carcinoma Identified by Proteomic Analysis* , 2002, Molecular & Cellular Proteomics.
[34] David E. Misek,et al. Proteomics-based identification of RS/DJ-1 as a novel circulating tumor antigen in breast cancer. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.
[35] R. Kobayashi. A proteomics approach to find a new breast cancer-specific antigenic marker. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.
[36] Benjamin Reiser,et al. mROC: a computer program for combining tumour markers in predicting disease states , 2001, Comput. Methods Programs Biomed..
[37] Faraggi,et al. Methodological issues associated with tumor marker development. Biostatistical aspects. , 2000, Urologic oncology.
[38] T. Soussi,et al. p53 Antibodies in the sera of patients with various types of cancer: a review. , 2000, Cancer research.
[39] P. V. van Diest,et al. Survival in early breast cancer patients is favorably influenced by a natural humoral immune response to polymorphic epithelial mucin. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[40] D. Jäger,et al. Cancer-testis antigens and ING1 tumor suppressor gene product are breast cancer antigens: characterization of tissue-specific ING1 transcripts and a homologue gene. , 1999, Cancer research.
[41] H. Joensuu,et al. Late mortality from pT1N0M0 breast carcinoma , 1999, Cancer.
[42] D. Ciocca,et al. Serological detection of heat shock protein hsp27 in normal and breast cancer patients. , 1998, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.
[43] I. Fentiman,et al. Autoantibodies to the 90kDa heat shock protein and poor survival in breast cancer patients. , 1998, European Journal of Cancer.
[44] B. Reiser,et al. Confidence intervals for the generalized ROC criterion. , 1997, Biometrics.
[45] S. Meijer,et al. Humoral immune response to polymorphic epithelial mucin (MUC-1) in patients with benign and malignant breast tumours. , 1996, European journal of cancer.
[46] A. Shevchenko,et al. Mass spectrometric sequencing of proteins silver-stained polyacrylamide gels. , 1996, Analytical chemistry.
[47] S. Ménard,et al. Antibody response against the c-erbB-2 oncoprotein in breast carcinoma patients. , 1993, Cancer research.
[48] W. Odling-Smee,et al. Screening for Breast Cancer , 1985, The Lancet.
[49] D. Pim,et al. Detection of antibodies against the cellular protein p53 in sera from patients with breast cancer , 1982, International journal of cancer.